WHSC1/NSD2 regulates immune infiltration in prostate cancer by Want, MY et al.
1Want MY, et al. J Immunother Cancer 2021;9:e001374. doi:10.1136/jitc-2020-001374
Open access 
WHSC1/NSD2 regulates immune 
infiltration in prostate cancer
Muzamil Y Want,1 Takemasa Tsuji,1 Prashant K Singh,2 James L Thorne   ,3 
Junko Matsuzaki,1 Ellen Karasik,4 Bryan Gillard,4 Eduardo Cortes Gomez,5 
Richard C. Koya,1 Amit Lugade,1 Kunle Odunsi,1 Sebastiano Battaglia   1
To cite: Want MY, Tsuji T, 
Singh PK, et al.  WHSC1/NSD2 
regulates immune infiltration 
in prostate cancer. Journal 
for ImmunoTherapy of Cancer 
2021;9:e001374. doi:10.1136/
jitc-2020-001374
 ► Additional material is 
published online only. To view, 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ jitc- 
2020- 001374).
Accepted 20 December 2020
1Center For Immunotherapy, 
Roswell Park Comprehensive 
Cancer Center, Buffalo, New 
York, USA
2Genomics Shared Resource, 
Roswell Park Comprehensive 
Cancer Center, Buffalo, New 
York, USA
3School of Food Science 
and Nutrition, Faculty of 
Environment, University of 
Leeds, Leeds, UK
4Department of Pharmacology 
and Experimental Therapeutics, 
Roswell Park Comprehensive 
Cancer Center, Buffalo, New 
York, USA
5Department of Biostatistics and 
Bioinformatics, Roswell Park 
Comprehensive Cancer Center, 
Buffalo, New York, USA
Correspondence to
Dr Sebastiano Battaglia;  
 sebastiano. battaglia@ 
roswellpark. org
Original research
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Background Immunotherapy in prostate cancer (PCa) 
lags behind the progresses obtained in other cancer 
types partially because of its limited immune infiltration. 
Tumor- resident immune cells have been detected in the 
prostate, but the regulatory mechanisms that govern tumor 
infiltration are still poorly understood. To address this gap, 
we investigated the role of Wolf- Hirschhorn syndrome 
candidate 1 (WHSC1), a histone methyltransferase enzyme 
that targets dimethyl and trimethyl H3K36. WHSC1 is 
known to promote malignant growth and progression in 
multiple tumors, but its role in the interface between PCa 
and immune system is unknown.
Methods RNA Sequencing (RNASeq) data from 
patients with PCa from The Cancer Genome Atlas 
(TCGA) were collected and divided into top/bottom 30% 
based on the expression of WHSC1 and disease- free 
survival was calculated. Publicly available chromatin 
immunoprecipitation (ChIPSeq) data were obtained from 
Cistrome and integrated with the available RNASeq 
data. RNASeq, ATACSeq and methylomic were analyzed 
using R Bioconductor packages comparing C42 cells 
with or without stable knockdown on WHSC1. Flow 
cytometry was used to measure Major Histocompatibility 
complex (MHC) levels, MHC- bound ovalbumin and tumor 
infiltration. C57B6 and NOD scid gamma (NSG) mice were 
subcutaneously grafted with TRansgenic Adenocarcinoma 
of the Mouse Prostate (TRAMP) C2 cells and treated with 
MCTP39 (10 mg/kg); tumor size was monitored over time 
and curves were compared using permutation analyses. All 
analyses used a significance threshold of 0.05.
Results Leveraging TCGA data, we demonstrated that 
elevated WHSC1 levels positively correlate with the 
presence of an immunosuppressive microenvironment. 
We validated those results in vitro, demonstrating 
that genetic and pharmacological inhibition of WHSC1 
restores antigen presentation. This occurs via an 
elegant epigenetic regulation of gene expression at the 
chromatin and DNA methylation levels. In vivo studies 
in immunocompetent mice also show an increased 
frequency of CD8+ T cells in tumors from mice treated 
with WHSC1 inhibitor, supporting the hypothesis that the 
antitumor effect following WHSC1 inhibition requires a 
fully functional immune system.
Conclusions This study demonstrates a novel role 
for WHSC1 in defining immune infiltration in PCa, 
with significant future implications for the use of 
immunotherapies in prostate malignancies.
INTRODUCTION
Prostate cancer (PCa) growth is intrinsically 
driven by the androgen receptor (AR), and 
androgen deprivation therapy (ADT) is a 
common therapeutic intervention aimed to 
reduced tumor size by blocking the androgen 
signaling. ADT also favors the establishment 
of an immunopermissive tumor microen-
vironment by promoting tumor homing 
of CD4+ and CD8+ T lymphocytes, natural 
killer (NK) cells and macrophage.1–3 Further-
more, parallel inhibition of the androgen 
pathway and FOXP3+ T regulatory (Treg) 
cells increases the response to anti- CTLA4, an 
effect that was not observed in the absence of 
ADT.4 These results support the concept of a 
tumor- driven immunosuppressive mechanism 
that reduces the ability of the immune system 
to recognize tumor cells. Although prom-
ising, these results are mainly descriptive and 
the actual mechanism by which PCa defines 
infiltrating moieties is still poorly understood; 
thus, identifying the determinants of immune 
cell infiltration into the prostate could shed 
light on the regulatory interface between PCa 
and the immune system.
The Wolf- Hirschhorn syndrome candidate 
1 (WHSC1) protein gene encodes for a SET- 
domain- containing histone methyltransferase 
that targets H3K36me2/me3.5–8 Elevated 
WHSC1 expression in the tumors correlates 
with worse prognosis, promoting resistance 
to chemotherapy and metastatic pheno-
type in PCa and other tumors.9–13 While the 
role of WHSC1 in tumor progression is well 
described, its role as epigenetic modifier in 
the crosstalk between PCa and the immune 
system remains mainly unexplored. In fact, 
the breadth of studies that investigate the 
regulatory role of WHSC1 on specific compo-
nents of tumor- resident immune pathways 
is limited. Elevated WHSC1 reduces Human 
Leukocyte Antigen (HLA) levels in malig-
nant peripheral sheath tumors in a mecha-
nism antagonistic to PRC214 and mediates 
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interferon- induced transcription through interaction 
with SPT6.15 Lastly, studies in cervical cancer revealed 
that WHSC1 promotes tumor progression and metastases 
by inducing transforming growth factor- beta (TGF-β)- 
mediated immunosuppression.16 Taken together, these 
results suggest that tumor- resident WHSC1 might act as 
the culprit for the poor antitumor immune response in 
PCa, which led us to investigate WHSC1’s role in defining 
the pathways regulating immune infiltration in prostate 
tumors.
In this paper, we examined the role of WHSC1 in regu-
lating tumor- resident immune pathways and we demon-
strate that the anti- tumor effect of WHSC1 inhibition is 




TRAMP C2 cells were a kind gift from Dr Barbara Foster17; 
they were maintained in Dulbecco's Modified Eagle 
Medium (DMEM) with 10% fetal bovine serum (FBS) 
supplemented with 1 nM Dihydrotestosterone (DHT), 
0.008 mg/mL insulin and penstrep. C42 cells were main-
tained in RPMI1640 with 10% FBS and P/S. C42 cells were 
validated via microsatellite PCR at the Roswell Genomics 
core. Both cell lines were mycoplasma negative.
WHSC1 knockdown
Short hairpin RNA (shRNA) knockdown of WHSC1 in 
C42 cells was prepared by the Roswell Park Gene Editing 
shared resource. Briefly, stable knockdown cells were 
generated using lentiviral- based shRNA (containing 
shRNA- pGIPZ plasmid or pGIPZ non- silencing control 
plasmid) produced in HEK293T cells as per manufacturer 
instructions. These lentiviral- based shRNAs express green 
fluorescent protein (GFP) and have a puromycin select-
able marker. For stable transduction of target cells, media 
from 70% confluent C42 cells were removed, and virus 
supernatant plus 4 μg/mL polybrene (total 1 mL for six- 
well plate) was directly added on top of the cells and the 
plate was sealed and centrifuged at 1800 rpm for 45 min at 
room temperature (RT). Next, the plate was incubated for 
3–6 hours at 37°C/5% CO2 and the media were replaced 
with normal target cell media and incubated again over-
night at 37°C/5% CO2. The next day, cells were split 1:5 
and were allowed to attach for 1 hour, and the media were 
replaced with puromycin selection media every 3–4 days 
(normal target cell media+puromycin (2 μg/mL). The 
resistant transduced C42 cells cultured for at least four 
to five passages in puromycin selection media and GFP 
expression were observed by microscopy before being 
using for further experiments.
Transient knockdown experiments in TRAMP C2 cells 
were made using SiWHSC1 (4390771, ThermoFischer 
Scientific) or SiCTR (4390843, ThermoFischer Scientific), 
and those in DU145 cells using siWHSC1 (SR305101) or 
siCTR (SR30004) from Origene.
For siRNA knockdown, 200×103 C42 cells or TRAMP C2 
cells in 200 μL optiMEM were plated in a 24- well plate over-
night and the next day were transfected with or without 
siWHSC1 (Invitrogen) using lipofectamine RNAimax at 
37C, 5% CO2. After 6 hours, media were gently aspirated 
and replenished with fresh RPMI1640 or DMEM supple-
mented with DHT and further incubated at 37°C, 5% CO2 
for 48 hours. Cells were harvested after 48 hours for RNA 
isolation using TRIzol (Invitrogen, 15596026) for quan-
titative PCR (qPCR) or for protein isolation by radioim-
munoprecipitation assay (RIPA) buffer for western blot. 
The concentration of RNA was measured by nanospec-
trometer, and for RT- qPCR, 2 ng/μL of RNA was used for 
cDNA synthesis using iscript cDNA synthesis kit (Biorad, 
170–8891). SYBR Green/Rox qPCR master mix (Ther-
moFischer Scientific, K0221) was used to analyze the 
expression of WHSC1, PDL-1, DNMT1 and GAPDH. The 
primer sequence is for these genes is provided in online 
supplemental table S2.
OVA overexpression
Soluble OVA gene, which was amplified from pCI- 
neo- sOVA (a gift from Maria Castro, Addgene plasmid 
25 09818), and monomeric enhanced green fluores-
cent protein (mEGFP) gene, which was amplified from 
mEGFP- N1 (a kind gift from Michael Davidson, Addgene 
plasmid 54767), were genetically fused via P2A transla-
tional skipping sequence and were cloned in the Sleeping 
Beauty transposon plasmid with the human elongation 
factor 1α promoter.19 This plasmid, pT2- EF- OVA- mEGFP, 
was electroporated together with the Sleeping Beauty 
Transposase plasmid, pCMV(CAT)T7- SB100 (a gift from 
Zsuzsanna Izsvak; Addgene plasmid #34 87920), into 
TRAMP- C2 by Nucleofector 4D instrument. The electro-
porated cells were kept in maintenance medium (DMEM 
supplemented with 10% FBS, 0.005 mg/mL bovine 
insulin, 1 nM DHT and cell sorted based on mEGFP 
expression using FACS Aria I cell sorter. The expression 
of OVA on sorted cells were confirmed by western blot-
ting using rabbit polyclonal OVA antibody (ab186717) at 
1:4000 dilution and flow cytometry using PE anti- mouse 
H- 2Kb bound to SIINFEKL (BioLegend) before incu-
bating with or without MCTP-39 for 48 hours. The expres-
sion of OVA was analyzed after 48 hours by flow cytometry 
using BDLSRIIA cytometer, and data were analyzed by 
FCS Express V.7 Research Edition.
Western blotting
Protein concentration was measured using bicinchoninic 
acid (BCA) kit and 30 μg of protein was loaded into 
sodium dodecyl sulphate- polyacrylamide gel electropho-
resis (SDS- PAGE) gel from either transfected or untrans-
fected C42 or TRAMP C2 cells. The protein from gel was 
transferred into PVDF and further incubated with human 
(anti- WHSC1, Abcam, ab225625) or mouse (anti- WHSC1, 
Abcam, ab75359) primary antibody to WHSC1 using 
1:2000 dilution for C42 lysate and 1:1000 for TRAMP C2 
protein lysate. The primary antibody was further detected 
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using either goat anti- rabbit (Abcam, dilution 1:10,000) 
or goat anti- mouse (Abcam, dilution 1:5000), while the 
house keeping gene, GAPDH, in both C42 and TRAMP 
C2 protein lysate was detected using anti- GAPDH anti-
body at 1:50 000 dilution (Abcam, ab181602).
Cell proliferation
Knockdown of WHSC1 in C42 and TRAMP C2 cells is 
discussed in previous sections. Cells were counted at 48, 
96 and 144 hours. For pharmacological inhibition, cells 
either C42 or TRAMP C2 were seeded overnight at 4×103 
cells per 100 μL media in a 96- well plate; the following 
day, cells were treated with vehicle control or different 
concentrations of MCTP-39 (0–10 μM) for 48 hours. 
After 48 hours, C42 or TRAMP C2 cells were either 
counted or used for staining with MHCI/II antibodies. 
Briefly, cells were detached using trypsin and washed 
with fluorescence- activated cell sorting (FACS) buffer for 
5 min at 300 g. The pellet was resuspended in FACS buffer 
and stained with MHC- I/II antibodies for 20 min at 4°C. 
After incubation, cells were washed with FACS buffer two 
times and resuspended in 200 μL of FACS buffer before 
acquiring the data on a flow cytometer.
Mice and in vivo experiments
Male C57B/6J mice (6–8 weeks of age) and NSG mice 
(10–12 weeks of age) were obtained from the Roswell 
Park’s Center For Immunotherapy breeding colonies. All 
in vivo experiments were made following institutional and 
Institutional Animal Care and Use Committee (IACUC) 
regulations. In vivo experiments were not blinded. 
TRAMP C2 cells (1 × 106 cells/100 μL) were injected 
subcutaneously into the right flank of male C57BL/6J 
mice (n=6/group) or NSG mice (n=5/group) using a 27 
G needle. Sample size was chosen based on pilot studies 
and chosen to include the potential loss of mice prior 
treatment. Tumor volume was monitored weekly with an 
electronic caliper and calculated as V=(W2×L)/2, where V 
is tumor volume, W is tumor width and L is tumor length. 
When tumors reached 100 mm3, mice were randomized 
prior to treatment with either MCTP-39 (10 mg/kg 5×/
week/4 weeks) or vehicle control. Mice were euthanized 
either when tumors reached 2000 mm in any dimen-
sion, as per institutional IACUC regulations, when mice 
showed signs of advanced disease or after 4 weeks of treat-
ment. Tumors were harvested and weighted; single cell 
suspension was prepared using the tumor dissociation 
kit (Miltenyi Biotech) as per manufacturing instructions 
prior to flow cytometry analysis.
Flow cytometry and antibodies
CD45- positive and CD45- negative fraction from single 
cell suspension was stained with the antibodies listed 
in online supplemental table S3. Gating strategies are 
described in online supplemental figures S4–S6). For C42 
cells and TRAMP C2, cells were trypsinized and washed 
with FACS buffer two times for 5 min at 300 g. The pellet 
of C42 or TRAMP C2 cells were resuspended in FACS 
buffer and C42 cells were surface stained with HLA- B7, 
HLA- F, HLA- E, and HLA- DQ, while TRAMP C2 cells were 
stained with a cocktail of I- A/I- E and H- 2Kb antibodies 
for 20 min at 4°C. To detect HLA- DM, C42 cells were 
first surface stained followed by fixation and permeabi-
lization followed by staining with anti HLA- DM antibody 
for 30 min at RT. Unstained C42 cells or TRAMP C2 cells 
were used as negative control. After incubation, cells were 
washed with FACS buffer two times and resuspended in 
200 μL of FACS buffer before acquiring data on BDLSRIIA 
cytometer. For mice, single cell suspension from tumors 
were incubated with anti- mouse CD16/32 antibody (FcR 
blocker) for 10 min at RT and subsequently stained with 
Zombie aqua for 15 min at RT followed by staining with 
anti- CD45, CD8a, CD3 and H- 2Kb for 20 min at 4°C. After 
staining, cells were washed and fixed with fixation buffer 
for 15 min at 4°C followed by washing two times with FACS 
buffer. Cells were resuspended in 200 μL of FACS buffer 
before acquiring data on flow cytometer. For compensa-
tion, the Ultracomp beads was used to stain for individual 
fluorochrome- conjugated antibodies as single- color 
compensation controls, and each drop of bead contained 
a positive population that captures fluorochrome- 
conjugated antibody and a negative population that does 
not react with antibody. This bimodal distribution was 
used a single- color compensation control in multiparam-
eter analyses. For the live/dead cell compensation, live 
cells were divided into two aliquots and saturating volume 
of methanol was added to one of the aliquots, vortexed 
and incubated at 4°C for 5 min. After 5 min, cells were 
washed three times with FACS buffer and mixed with 
original aliquot of live cells to get the heterogenous popu-
lation of live/dead cells that was used for compensation 
in flow cytometry. Data were analyzed using FCS express 
V.7 Research Edition.
Analysis of published datasets
Publicly available PCa datasets were retrieved from cBio-
portal (https://www. cbioportal. org/). Detailed statistical 
methods are explained further in the appropriate section. 
GSEA analysis on TCGA data was done using the package 
DOSE,21 clusterprofiler22 and enrichplot (https:// github. 
com/ GuangchuangYu/ enrichplot) using Reactome gene 
signature downloaded from the GSEA website (https://
www. gsea- msigdb. org/ gsea/ index. jsp). To create the 
antigen processing and presentation signature, the 
following gene sets were used: REACTOME ANTIGEN 
PROCESSING CROSS PRESENTATION, REACTOME 
ANTIGEN PROCESSING UBIQUITINATION PROTE-
ASOME DEGRADATION, REACTOME MHC CLASS II 
ANTIGEN PRESENTATION, REACTOME ANTIGEN 
PRESENTATION FOLDING ASSEMBLY AND PEPTIDE 
LOADING OF CLASS I MHC, REACTOME CLASS I 
MHC MEDIATED ANTIGEN PROCESSING PRESENTA-
TION. ChIPSeq data were downloaded from Cistrome 
(http:// cistrome. org/) with the following accession 
numbers: GSM1527830, GSM1679107, GSM353624, 
GSM353627, GSM875813, GSM875814, GSM1679108, 
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GSM2252903, ENCSR849APH_1, and ENCSR849APH_2. 
Predicted target genes from Cistrome that scored 0 were 
removed, leaving a total of 13 878 unique genes (online 
supplemental file S2). Differential gene expression anal-
ysis from TCGA data comparing patients with highversus 
low WHSC1 transcript levels was performed using the 
limma R package at a significance level of FDR<0.05 and 
LogFC 0.25.23 Precomputed TCGA immune infiltration 
data were downloaded from xCell.24
RNASeq
RNA extraction and library preparation were performed 
by the Roswell Park Genomics Shared Resources. RNA 
libraries were constructed using the KAPA mRNA Hyper-
Prep Kit (Roche Sequencing Solutions), and the libraries 
were sequenced on the Illumina NextSeq 500 sequencer 
with 2×75 cycle sequencing. Raw reads were compiled 
into fastq files, mapped onto the human hg38 reference 
genome using STAR25 and quantified at the gene level 
using the tximport R package.26 Genes differentially 
expressed between conditions were identified using 
limma.23 GSEA analysis was performed as described 
previously. APM signature was generated using HLA 
genes and genes involved in the antigen processing and 
presentation.
ATACSeq
ATACSeq was run on C42 cells with stable knockdown 
of WHSC1 via shRNA and control. The ATACSeq 
libraries were sequenced using NextSeq 500 sequencer 
at 2×75 cycle sequencing. Raw data were processed with 
MACS227 28 and further processed using ChIPSeeker29 to 
annotate identify the genes within the genomic regions 
within ATAC peaks. To calculate the fold changes 
between the two conditions, we created a consensus list of 
genomic regions covered by both conditions (shCTR and 
shWHSC1) using the soGGi R Bioconductor package.30 
Reads spanning over these regions were then quantified 
using Rsubread,31 summarized at the gene level using 
peaks that are within 1000 bp to the nearest TSS and used 
to calculate the log2FC between WHSC1 knockdown and 
control. Results were merged with the RNASeq DEGs to 
identify genes that positively correlate with RNASeq data, 
hence higher ATAC signal, higher gene expression. The 
ATACSeq log2FC was then used to rank genes used as 
input for GSEA analysis using the GO signature. GSEA 
analysis was run in R using the clusterprofiler package 
and a p value cut- off of 0.05.
Methylation analysis
Methylation analysis was run on C42 cells with stable 
knockdown of WHSC1 via shRNA and control using 
the Illumina Infinium MethylationEPIC BeadChip Kit 
(Illumina). Raw files were processed using the Champ 
Bioconductor R package32 using default parameters. 
Methylation probes that coincided with known SNPs 
were removed. Probe IDs from the differentially methyl-
ated probe (DMP) list were merged with RNASeq DEG 
data, aggregated using mean intensity values at the gene 
level and correlated with RNASeq log2FC results to iden-
tify genes with reduced methylation and increased gene 
expression, or vice versa, on WHSC1 knockdown.
Statistical methods
Survival analysis was performed dividing patients based 
on the upper/lower 25% of the expression levels of 
WHSC1; significance, HR and CIs were calculated 
using Cox proportional hazard model available in the R 
package survival.33 The AUC analysis to evaluate WHSC1 
as predictor for biochemical recurrence was done using 
the R package survivalROC,34 censoring for biochemical 
recurrence. Since TCGA does not offer the history of PSA 
testing per each patient over time, we used a threshold 
of PSA>0.4 ng/mL as described in Brockman et al.35 
Significance for the AUC analysis was calculated by simu-
lating 10 000 AUCs using randomly selected genes in the 
RNASeq dataset. The empirical p value was calculated 
by dividing the number of expected/simulated AUCs 
higher than our observed value by 10 000 (number of 
simulations).36 Significance when comparing two groups 
was calculated via two- tailed Student’s t- test at a signifi-
cance threshold of 0.05. When more than two groups 
were compared, one- way analysis of variance with Tukey’s 
post hoc correction was used at a significance threshold 
of 0.05. In both cases, bar plots indicated the mean and 
SE of at least three biological replicates unless specified 
otherwise. The correlation between WHSC1 and AR gene 
expression was calculated using Spearman correlation 
using the log2 expression values from TCGA RNASeq 
data. Growth curves in mice were compared using 
permutation test with 10 000 simulations via the statmod 
R package using the compareGrowthCurves function.37 38
RESULTS
WHSC1 levels positively correlate with the presence of an 
immunosuppressive microenvironment in PCa
We first evaluated WHSC1 expression in 489 PCa samples 
from The Cancer Genome Atlas (TCGA) collected 
following radical prostatectomy39 (online supplemental 
table S1) and its association with patients disease- free 
survival (DFS). This analysis revealed that patients with 
elevated WHSC1 expression (top 25%, online supple-
mental file S3) have significantly shorter DFS than 
patients with low WHSC1 levels (bottom 25%) (figure 1A 
and online supplemental figure S1A) (Cox p=0.000121, 
Cox HR=3.2221, 95% CI 1.801 to 6.127). Raising prostate- 
specific antigen (PSA) concentration post- therapy in PCa 
are often indicative of disease recurrence,35 and we found 
that WHSC1 gene expression levels are a modest, but 
significant, predictor for biochemical recurrence with 
an area under the curve (AUC) of 0.742 (online supple-
mental figure S1B,C; empirical p=0.0046). Moreover, PCa 
is an androgen- driven disease, and we found a positive 
correlation between WHSC1 and AR expression (online 
supplemental figure S1D) (Spearman’s coefficient=0.397, 
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p<2.2e-16), corroborating previously published data on 
WHSC1 function as a transcriptional regulator of AR.13 
We then investigated whether WHSC1 expression levels 
correlate with the presence of specific immune popula-
tions and found that patients with elevated WHSC1 have 
a highly immunosuppressive tumor microenvironment 
composed of high Th2 and Treg and low Th1 cells, NKT 
cells and M1 macrophages (figure 1B) (p value<0.001, 
Student’s t- test). Next, we interrogated TCGA RNA 
Sequencing (RNASeq) data to evaluate whether different 
WHSC1 levels correlate with altered HLA expression in 
the tumor, which would undermine the tumor’s ability to 
present tumor antigens to the immune system. Indeed, 
patients with elevated WHSC1 were found with consis-
tently low levels of HLA class I and class II transcripts 
(figure 1C). We then investigated which transcriptional 
pathways were altered in patients with high versus low 
expression of WHSC1. Gene set enrichment analysis 
(GSEA) revealed that patients with elevated WHSC1 have 
increased expression of genes involved with cell prolif-
eration pathways such as cell division, DNA replication 
and DNA repair (figure 1D), corroborating the results 
from previous studies.9 10 13 However, we also identified 
a downregulation of pathways involved with response 
to interferon gamma (IFN-γ), antigen processing 
and presentation and cytokine secretion (figure 1E), 
suggesting that high levels of WHSC1 negatively correlate 
with the status of both tumor- resident immune pathways 
and the antigen processing and presentation machinery 
(APM), which we previously demonstrated as a determi-
nant of T cells’ ability to recognize neoantigens.40
Immune and APM genes are transcriptionally regulated by 
WHSC1 in PCa
We sought to pinpoint potential mechanistic events 
that allow WHSC1 to regulate the expression of APM 
genes. To this end, we downloaded publicly available 
ChIPSeq data for PCa cell lines from the Cistrome data-
base41 42 and generated a consensus list of genes residing 
in H3K36me2 and H3K36me3 loci as proxy for WHSC1 
targets, exploiting the fact that WHSC1 can deposit 
both H3K36me2 and H3K36me3 marks.7 We ran differ-
ential gene expression analysis for this signature in the 
TCGA PCa dataset comparing patients with high versus 
low WHSC1 levels. A total of 5788 genes were differen-
tially expressed, including ubiquitinases, proteases and 
HLAs, involved with protein and antigen processing, 
DNA methylatransferases and immune genes (figure 2). 
Notably, patients with low WHSC1 tend to present with 
high expression of HLA- C and HLA- F, low CD276/B7H3 
Figure 1 Exploratory analysis of TCGA data focused on WHSC1. (A) Kaplan- Meier plot showing disease free survival 
comparing patients with high versus low expression levels of WHSC1 using the TCGA PCa cohort. Patients were divided based 
on the top/bottom 25% gene expression, Cox HR, p value and median survival were calculated for the two groups and are 
shown on the plot. (B) Predicted infiltration levels of immune cells in TCGA PCa data using precomputed data from xCell. High 
and low (red and blue) refer to patients with the top/bottom 25% of WHSC1 expression. P value shown in figure, calculated with 
two- tailed Student’s t- test, n=125/group. (C) Heatmap showing HLA expression in the TCGA PCa cohorts. Red and black cells 
indicate upregulated and downregulated genes, respectively. Side annotation indicates the patients’ groups based on WHSC1 
expression levels. (D,E) GSEA analysis comparing patients with high versus low WHSC1 levels highlighting upregulated (C) and 
downregulated (D) pathways in patients with elevated WHSC1 expression levels. GSEA, gene set enrichment analysis; NES, 
normalized enrichment score; IFN-γ, interferon gamma; NA, not applicable; PCa, prostate cancer; TCGA, The Cancer Genome 
Atlas; WHSC 1, Wolf- Hirschhorn syndrome candidate 1.
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Figure 2 Differential gene expression analysis in TCGA data. (A) Heatmap of degS within H3K36me3 and H3K36me2 loci 
identified using ChIPSeq data from Cistrome and RNAseq data from TCGA. Red and green indicate high and low expression 
levels, respectively. Blue and red annotations indicate patients with low and high WHSC1 gene expressions, respectively. 
Columns are clustered using Pearson correlation, and rows are ranked based on log2FC comparing tumors with low versus high 
WHSC1. Black arrows indicate selected genes (DNMTs, CD274, B2M, HLAs and WHSC1). RNASeq, RNA Sequencing; TCGA, 
The Cancer Genome Atlas; WHSC 1, Wolf- Hirschhorn syndrome candidate 1.
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and CD274/PDL1, and low DNMT1, DNMT3A and 
DNMT3B levels (figure 2). To validate our computational 
observations, we stably knocked down WHSC1 in C42 
cells and noted a significant reduction in cell prolifera-
tion (online supplemental figure S2A), also observed on 
transient knockdown of WHSC1 in DU145 cells (online 
supplemental figure S2B). On WHSC1 knockdown, 3783 
genes were differentially expressed (1834 down and 
1949 up, false discovery rate (FDR)<0.05) (figure 3A). 
We first confirmed the downregulation of AR and its 
downstream target KLK2, indicating a transcriptional 
suppression of the androgen signaling (figure 3B). GSEA 
analysis revealed a downregulation of TGF-β signaling 
and upregulation of IFN-γ and tumor necrosis factor 
signaling (figure 3C). The APM signature, curated from 
the Reactome database, was also upregulated on WHSC1 
knockdown (figure 3D). At the gene level, we noticed an 
increase in HLAs, proteinases and ubiquitinase genes, 
parallel to a downregulation of DNMT1 and CD276 
(figure 3E), consistent with the initial computational 
observations. A number of differentially expressed genes 
(DEGs) were common with those identified integrating 
ChIPSeq and TCGA data, including UBL5, UBXN1, 
UBA52, PSME1, UBE2N, PSMC5, UBL7, UBE2E3, UBR7, 
UBR3 and UBE4A, suggesting that protein processing 
and degradation could be directly regulated by WHSC1 
via methylation of the H3K36 histone mark. The degree 
of dissimilarity at the gene level between the predicted 
H3K36me2- H3K36me3 Cistrome and the DEGs following 
WHSC1 knockdown is likely caused by the different 
biological sources from which data were originated 
(Cistrome/cell lines vs TCGA/patient biopsies) and by 
the fact that multiple enzymes can methylate H3K36.43–48 
These results support a mechanistic role for WHSC1 in 
regulating the expression of APM genes in PCa.
WHSC1 regulates protein degradation and immune 
components via DNA methylation
Our computational and transcriptional analyses indicate 
that one of the mechanisms by which elevated WHSC1 
regulates target gene expression is by upregulating 
DNMT1, corroborating previous studies indicating a link 
between H3K26me2 and DNA methylation.49 To evaluate 
the link between DNA methylation and the expression of 
genes in immune pathways or APM, we performed methy-
lomic analyses in C42 cells following WHSC1 knockdown 
(figure 4A,B).
A total of 2209 DEGs contained differentially meth-
ylated probes, and in 651 genes, changes in transcript 
levels negatively correlated with changes in DNA meth-
ylation on WHSC1 knockdown (figure 4C,D). In accor-
dance with the data presented earlier, the results includes 
six genes involved in peptide proteosomal degradation 
(UBE2E1, UBE2E6, UBE2L6, UBE4A, RNF135 and 
Figure 3 Transcriptional analysis of WHSC1 knockdown in C42 cells. (A) RNAseq analysis in C42 cells following shRNA 
knockdown of WHSC1. Red dots indicate genes with FDR<0.05 (B) Box plots showing the expression levels of Ar and 
KLK2 following WHSC1 knockdown, p value on figure calculated with limma, n=3/group. (C) GSEA indicating pathways 
downregulated and upregulated following knockdown of WHSC1. (D) GSEA analysis using a custom APM- MHC gene signature 
(E) Heatmap showing expression of HLAs, DNA repair genes and DNMT1 in C42 comparing knockdown versus control. Red 
and cyan cells indicate high and low expression levels, respectively. Black arrows highlight HLAs, DNMT1, CD276 and WHSC1 
transcripts. APM, antigen processing and presentation machinery; AR, androgen receptor; GSEA, gene set enrichment analysis; 
IFN-γ, interferon gamma; MHC, Major Histocompatibility complex; shRNA, short hairpin RNA; TGF-β, transforming growth 
factor- beta; WHSC 1, Wolf- Hirschhorn syndrome candidate 1.
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PSMD8); RUNX1, which is involved in promoting class I 
Major Histocompatibility complex (MHC) expression50; 
SMAD7, which negatively regulates the immunosuppres-
sive TGF-β signaling (reviewed in Stolfi et al51); a number 
of membrane trafficking proteins (SRL, RIMS1, STXBP6, 
and NAPB); interleukin (IL)- 6R, increased during PCa 
development52 and in breast cancer53; INHBB, which 
belongs to the TGF-β family and is increased in PCa54; 
IL-5, which was shown to promote cancer metastases 
modulating the TME55 56; PARP10, which limits cell 
proliferation and metastases57; and CD276, which is 
elevated in several cancers and is a potential immuno-
therapeutic target.58–60 Lastly, we noticed that probes 
associated with the DNMT1 gene had increased methyl-
ation with a parallel reduction in DNMT1 gene expres-
sion (figure 4D). These results suggest that WHSC1 can 
regulate tumor- resident immune pathways and APM by 
altering the DNA methylation landscape in PCa.
WHSC1 epigenetically regulates genes in the APM by 
changing chromatin status
To further narrow the mechanistic role of WHSC1 in 
modulating APM genes, we performed ATACSeq anal-
ysis of C42 cells following knockdown of WHSC1. We 
first created a consensus peak list, compared the peak 
intensity between the two conditions and noticed that 
the biggest differences were, as expected, in the peaks 
for mononucleosomal or dinucleosomal regions with no 
differences in larger peaks (figure 5A,B). After annotating 
genes to the peaks, we kept those with open chromatin 
and increased gene expression, or vice versa, as indicated 
by a positive correlation between the log fold changes in 
ATACSeq and RNASeq (figure 5C), and performed GSEA 
analysis. Within the results (online supplemental file S1), 
we identified upregulation of genes in immune signaling 
and protein ubiquitination pathways (figure 5D,E). Next, 
we evaluated the presence of peaks at the gene level for 
the core enrichment of the upregulated pathways and 
demonstrated that increased peak magnitude at the tran-
scriptional start site (TSS) is associated with increased 
gene expression (figure 5F). Interestingly, while the 
results between the H3K36 Cistrome, ATACSeq and DNA 
methylation have a modest overlap, genes consistently 
belong to immune and antigen processing pathways. This 
suggests that WHSC1 plays complementary direct and 
indirect roles in regulating cellular behavior by modifying 
chromatin accessibility and DNA methylation in cancer.
Figure 4 Methylomic data analysis following WHSC1 knockdown in C42 cells. (A) Distribution of the beta values in our 
methylomic analysis. (B) PCa analysis of the normalized methylation data; values were scaled and centred prior to PCa analysis. 
Blue and red dots indicate controls (shCTR) and knockdown (shWHSC1) samples, respectively. (C) Scatterplot showing the 
relationship between the changes in percentage methylation and gene expression following WHSC1 knockdown. Red dots 
highlight genes with negative correlation (high methylation, low expression and vice versa) that were selected (D) Heatmap 
visualization of the methylation intensity versus expression values, highlighting genes that belong to immune and APM 
pathways. For methylation data (left), orange and blue indicate high and low intensity/beta values, respectively; for RNAseq 
data, red and cyan indicate high and low gene expression, respectively. APM, antigen processing and presentation machinery; 
CTR, control; PCa, prostate cancer; WHSC 1, Wolf- Hirschhorn syndrome candidate 1.
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WHSC1 and DNMT1 expression reflect tumor phenotype in 
vivo
Following the results from computational and in vitro 
experiments, we sought to evaluate in vivo whether the 
pattern of expression of WHSC1 and companion markers 
was conserved. Prostate samples were isolated from 
TRAMP mice61 with tumors at 20/25 weeks of age, with 
aggressive palpable tumors (~35 weeks) and healthy wild 
type (WT) mice. The protein levels of WHSC1, DNMT1, 
H3K36me2 and CD274/PD- L1 were evaluated via western 
immunoblotting. CD274 was included since it is elevated 
in patients from TCGA with high WHSC1 levels (figure 2) 
and is a downstream target of IFN-γ,62 63 which is elevated 
on WHSC1 knockdown (figure 3C). Furthermore, CD274 
has potential translational relevance as target for check-
point inhibitor therapy. Results show that healthy WT 
prostates have no detectable expression of any of the 
aforementioned proteins while higher levels of DNMT1, 
WHSC1, CD274/PD- L1 and H3K36me2 are detected 
in the tumor samples via western blot (figure 6A). We 
then tested whether the effect of WHSC1 knockdown in 
human C42 cells was reproducible in the murine TRAMP 
C2 cells,17 as proxy for potential in vivo effects. Knock-
down of Whsc1 via siRNA led to a significant reduction 
in cell proliferation (online supplemental figure S3A,B) 
and increased transcript levels of DNMT1 and CD274 
(figure 6B).
Pharmacological inhibition of WHSC1 upregulates MHC 
molecules and increases immune infiltration in vivo
Since we detected increased MHC transcript levels 
following WHSC1 knockdown, we investigated whether 
this observation can be replicated at the protein level on 
pharmacological inhibition of WHSC1 (with MCTP-399) 
in both human (C42) and murine (TRAMP C2) cell lines. 
The combined treatment with MCTP-39 and IFN-γ had an 
additive effect on upregulating HLA- B7, HLA- F, HLA- E, 
HLA- DQ, HLA- DM (figure 7A) and murine H2Kb I- A/
I- E (figure 7B), as measured via flow cytometry analysis. 
We then tested whether antigen- bound MHC was also 
elevated on WHSC1 inhibition using ovalbumin (OVA)- 
overexpressing TRAMP C2 cells, and demonstrated that 
treatement with MCTP39 increased the OVA- bound 
H2Kb fraction (figure 7C,D). These results suggest that 
pharmacolocycal inhibition of WHSC1 increases PCa 
cells’ ability to present processed antigens on the cell’s 
surface via upregulation of MHC molecules.
Functional immune system is needed to mediate anti-WHSC1 
tumor growth
Hypothesizing that higher tumor antigen presentation would 
affect tumor growth and the levels of infiltrating immune cells 
in the tumor, we grafted C57B/6 mice with TRAMP C2 cells, 
administered MCTP39 (10 mg/kg) for 4 weeks intraperito-
neally and evaluated tumor size weekly and T- cell infiltration 
Figure 5 ATACSeq analysis in C42 cells with stable knockdown of WHSC1. (A) ATAC seq log2FC obtained by calculating the 
difference in read abundance from common loci in control and knockdown cells. (B) Summary of the log2FC versus fragment 
length, with the red lines indicating the periodicity of the nucleosomes. (C) Correlation between log2FC in ATACSeq and 
RNAseq data; each dot is a gene; highlighted in purple are genes showing positive correlation between the two datasets. (D) 
GSEA analysis using the aforementioned data. (E) Box plots indicating gene expression in the genes involved in the upregulated 
pathways (n=3/group, FDR values on figure, calculated with limma) (F) ATACSeq reads for representative genes confirming 
increased peaks in red boxes following knockdown of WHSC1. GSEA, gene set enrichment analysis; PCa, prostate cancer; 
WHSC 1, Wolf- Hirschhorn syndrome candidate 1.
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at endpoint. Tumor growth was significantly reduced on 
treatment with MCTP39 (figure 8A) (p=0.0023), while this 
inhibitory effect was not observed when we grafted the same 
number of TRAMP C2 cells in immunocompromised NSG 
mice (figure 8B). Moreover, the reduction in tumor growth 
in C57B/6 mice was accompanied by increased H2Kb 
expression, increased CD8+ T- cell infiltration and reduced 
tumor weight (figure 8C). These results indicate that that 
Figure 6 Expression of WHSC1 in murine samples. (A) Protein data from prostates isolated from WT and TRAMP mice at 
different stages of PCA development testing the protein levels for WHSC1, DNMT1, CD274 and H3K36me2. (B) qPCR validation 
for DNMT1 and CD274 following WHSC1 knockdown (n=3/group, two- tailed Student’s t- test). *P<0.05. qPCR, quantitative PCR; 
WHSC 1, Wolf- Hirschhorn syndrome candidate 1.
Figure 7 Effect of WHSC1 inhibition on antigen presentation. (A,B) Flow cytometry analysis of MHC expression levels on 
pharmacological WHSC1 inhibition and IFN-γ treatment in human C42 (A) and murine C2 (B) cells (n=3/group, one- way analysis 
of variance with post hoc Tukey correction). *P<0.05, **P<0.01, ***P<0.001. (C) Flow plot showing increased H2Kb- bound to 
OVA following treatment with MCTP39 and its quantification (right bar plot). IFN-γ, interferon gamma; OVA, ovalbumin; WHSC 1, 
Wolf- Hirschhorn syndrome candidate 1.
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the antitumor effect observed following Whsc1 inhibition 
requires the presence of a functional immune system for 
optimal tumor control.
DISCUSSION
The use of immunotherapy in PCa has been pioneered 
by the use of vaccines targeting the PSA (Sipuleucel T/
Provenge)64 or the prostate acid phosphatases (Prostvac 
VF)65 that showed significant clinical benefits for patients 
with metastatic PCa. However, there is still an incomplete 
understanding of the regulatory interface that mediates 
the infiltration of T cells into the prostate. The relevance 
of filling this gap in knowledge is highlighted by nega-
tive results or minimal benefits recorded in subsequent 
clinical trials testing immunotherapeutic approaches 
in patients with PCa.66–72 Therefore, a thorough under-
standing of the mechanism by which PCa evades the 
immune system and limits T- cell infiltration could have 
significant translational consequences.
Here we presented an epigenetic tumor- driven mech-
anism by which prostate tumors remain relatively 
cold due to increased levels of the epigenetic enzyme 
WHSC1. While the role of tumor WHSC1 in PCa has 
been investigated by other groups,9 13 73 74 we offer a 
novel complementary evidence of its role in promoting 
immune evasion by rendering tumor cells less visible to 
the immune system. This is achieved by an elegant and 
coordinated downregulation of MHC molecules and 
APM genes through alteration of the chromatin status 
and by modifying the methylation of APM genes.
We first used bioinformatics approaches to investi-
gate the relationship between the transcript levels of 
WHSC1 and genes in immune- related pathways mining 
publicly available data. Using RNASeq data from TCGA, 
we demonstrated that patients with PCa with increased 
WHSC1 transcript levels have shorter time to recurrence 
and lower expression of HLAs, and tend to have an immu-
nosuppressive tumor microenvironment. By integrating 
TCGA RNASeq data with H3K36 methylation data from 
different PCa cell lines, as proxy for WHSC1 activity, we 
identified HLAs, DNMTs, ubiquitinases and proteosomal 
and immune genes as candidate targets of WHSC1. 
Following knockdown of WHSC1 in vitro, we confirmed 
a pattern in which HLAs; ubiquitinases and proteosomal 
genes were mostly upregulated, while DNMT1 and 
CD276 were downregulated. This pattern of expression is 
remarkably consistent with the TCGA/Cistrome results, 
suggesting that WHSC1 regulates protein degradation, 
Figure 8 In vivo effect of WHSC1 inhibition on tumor growth and T- cell infiltration. (A) Growth curve of TRAMP C2 cells 
grafted in C57B/6 mice treated with MCTP39 for 4 weeks. Blue and red lines indicate growth in control and MCTP39- treated 
mice, respectively. n=6/group, p=0.0023, permutation test. (B) Growth curve of TRAMP C2 cells in NSG mice following 4 weeks 
treatment with MCTP39. Black and gray lines indicate growth in control and MCTP39- treated mice, respectively. P=0.1461, 
permutation test. (C) Quantification of flow cytometry data in tumors at endpoint evaluating, from left to right, CD8+ T- cell 
infiltration, H2Kb expression on the tumor and tumor weight in gram in C56B/6 mice. n=6/group, two- tailed Student’s t- test. 
*P<0.05, **P<0.01. NS, not significant; WHSC 1, Wolf- Hirschhorn syndrome candidate 1.
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antigen processing and presentation, while potentially 
altering DNA methylation via DNMT1. Our RNASeq 
results also confirmed a downregulation of AR and KLK2, 
suggesting that inhibition of WHSC1 in C42 cells limits 
AR signaling, corroborating previous studies showing 
increased immune infiltration in the tumor following 
ADT.1–3 While complementary to our study, previous 
studies did neither investigate nor identify the tumor- 
resident immune pathways that define the interface 
between prostate tumors and immune system. To this 
end, we corroborated the RNASeq results via flow cytom-
etry analysis, demonstrating that silencing of WHSC1 
increased MHC expression on PCa cells, augmenting 
the levels of MHC- bound antigen on the cell’s surface. 
Consequentially, we observed increased T- cell infiltration 
in grafted tumors following pharmacological inhibition 
of WHSC1 with MCTP39, which correlated with reduced 
tumor growth. Previous studies using DU145 xenografts 
also showed reduced tumor weight on MCTP39 treat-
ment,9 but the use of immunocompromised mice did 
not allow capturing of any effect on the immune system. 
The TRAMP C2 cells were shown to be a reliable subcu-
taneous in vivo model for studying the behavior of the 
immune system in PCa in response to therapy.75–78 In our 
study, we used immunocompetent C57B/6 mice grafted 
with syngeneic TRAMP C2 cells and found reduced tumor 
weight, increased T- cell infiltration and increased MHC 
expression in treated tumors. The observed changes in 
T- cell infiltration and MHC expression are consistent 
with the induction of an antitumor immune response. 
Furthermore, we tested whether a similar magnitude in 
tumor reduction was observed in immunocompromised 
mice and found only a limited and non- significant effect 
of MCTP39 in delaying tumor growth. While this suggests 
that the immune system plays a certain role in mediating 
the observed antitumor effect, more studies are needed 
to pinpoint the exact immune populations responsible 
for this effect. Since NSG mice lack of T, B and NK and 
have a mutation in the C5 component of the complement 
pathway, impairing complement- dependent cytolysis, it is 
possible that the reduction in tumor growth observed in 
immunocompetent mice is the result of the coordinated 
action of multiple immune cell types. To this point, we 
demonstrate that, following WHSC1 inhibition, there is 
higher antigen presentation in vitro and higher T- cell 
infiltration in vivo. This suggests that T cells are the most 
likely driver of the antitumor response that we observed.
Mechanistically, we demonstrate a close relationship 
between WHSC1 and DNMT1 expression, suggesting a 
role for WHSC1 in maintaining the DNA methylation 
status in PCa. A similar relationship was shown between 
H3K36me2 and DNA methylation, where ablation of 
Nsd1 and Nsd2 in mouse changes the genomic local-
ization of DNMT3A, which is redeployed intragenically, 
leading to reduced intergenic methylation levels.49 This 
happens because of changes in the methylation status 
of H3K36me2, which is required for efficient DNMT3A 
binding. While our results do not directly indicate which 
DNA methyltransferase enzyme drives the changes we 
observed, RNASeq data point to DNMT1, which is located 
within H3K36me2- H3K36me3 loci and is downregulated 
following WHSC1 knockdown. Lastly, due to the effect 
of WHSC1 on cellular proliferation, we acknowledge 
that a degree of the observed changes in the epigenome 
might be secondary to the reduced proliferative potential 
following WHSC1 inhibition.
WHSC1 casts a broad regulatory net that affects a 
heterogeneous panel of genes and cellular pathways. 
First, it appears to have complementary, yet separate, 
mechanisms of action that mold the epigenetic land-
scape of PCa cells by altering chromatin accessibility 
and DNA methylation. At the gene level, WHSC1 alters 
ubiquitinases and proteosomal genes, which mediate 
protein degradation and generate potentially antigenic 
peptides. The upregulation of immune and MHC genes 
following WHSC1 inhibition suggests that processed 
peptides can then reach the cell’s surface for recogni-
tion by the immune system. WHSC1 also controls the 
expression of CD274/PD- L1 and CD276. Although 
CD274/PD- L1 is regulated by IFN-γ following immune 
activation,62 63 it is also indicative of T- cell exhaustion 
and is overexpressed in numerous tumors favoring an 
immunosuppressive microenvironment,79 80 similarly to 
CD276.58–60 This suggests that WHSC1 has the potential 
to limit the antitumor immune response to the tumor 
microenvironment by different, yet complementary, 
mechanisms.
In conclusion, here we offer a novel function for 
WHSC1/NSD2 as key regulator of tumor- resident 
immune pathways, and WHSC1 pharmacological inhi-
bition has the potential to act as a potent adjuvant for 
combination immunotherapy in PCa.
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Age 61.006 +/- 6.82
Sex male = 500
Race Asian = 2
Black or African American = 7
White = 147
Not avaiable = 344
Overall Survival (months) 35.87 +/- 25.96
Disease Free Survival (months) 32.3 +/- 24.96
Not avaiable = 6











Last PSA recording 1.742 ng/mL +/- 15.8
Table S1
* Mean +/- sd for continuous variables 
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Table S2
Name FW primer RW primer
Hu_WHSC1 Forward: 5/-AGCAACGAAAAATCTGTCTG-3/ Reverse:  3/-ACTTTTGCTAAACCCAAGAG-5/
Hu_GAPDH Forward: 5/-ACAGTTGCCATGTAGACC-3/ Reverse: 3/--TTGAGCACAGGGTACTTTA-5/
Hu_PDL1 Forward: 5/-TCACTTGGTAATTCTGGGAGC-3/ Reverse: 3/-CTTTGAGTTTGTATCTTGGATGCC-5/
Hu_DNMT1 Forward: 5/-ATGCCGCGCCGTACCGC-3/ Reverse: 3/-CAACATACAAAGCTTGATCTCC-5/
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Antibody Clone Company Cat no
Ax700 antimouse CD45 30-F11 Biolegend 103128
FITC anrimouse CD3 145-2C11 Biolegend 100305
PerCPCy5.5 antimouse CD8a 53-6.7 Biolegend 100734
APC/Fire750 antimouse CD4 GK1.5 Biolegend 100459
APC antimouse H-2Kb AF6-88.5 Biolegend 116518
PE antimouse H-2Kb SIINFEKL 25-D1.16 Biolegend 141604
APC anti human HLA-B7 BB7.1 Biolegend 372405
PE antihuman HLA-DQ HLA-DQ1 Biolegend 318105
PE antihuman HLA-DM MaP.DM1 Biolegend 358003
PE-Cy7 antihuman HLA-E 3D12 Biolegend 342607
APC antihuman HLA-F 3D11 Biolegend 373207
PE anti-mouse H-2Kb AF6-88.5 Biolegend 116518
APC anti-mouse H2-Kb bound SIINFIKL 25-D1.16 Biolegend 141606
Table S3
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Figure S4
FSC-A (x 1000)
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Figure S5.
FSC-A (x 1000)
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